New Stock News | Zehui Biotech, a biopharmaceutical company, is reportedly planning to go public in Hong Kong in the third quarter.

According to market news, Zehui Biotech, a biopharmaceutical company focusing on the research and development of stem cell drugs, plans to go public in Hong Kong in the third quarter of this year. After several rounds of financing, investors in Zehui Biotech include CAS Star Science, Jianxin Trust, Guangdong Science and Technology Mother Fund, Guoke Jiahe, Zhongshan Torch, Zhenji Capital, Bencao Capital, and Shanxi Growth Fund. Data shows that Zehui Biotech currently has a presence in two areas: human embryonic stem cells and induced pluripotent stem cells. The company has a world-class GMP stem cell drug production plant and is equipped with complete cell culture and testing facilities. The company has established a sound stem cell drug quality management system and has successfully conducted process research and quality research on stem cell products, fully meeting the demand for safe, reliable, and high-quality stem cell drugs for domestic patients. Based on the characteristics of the products, Zehui Biotech's product pipeline includes products for treating diseases such as meniscus injury and acute respiratory distress syndrome, which currently lack effective treatment methods. Among them, CAStem stem cell injection is a self-developed injection product composed of immune and stromal regulating cells, with its main component being M cells derived from clinical-grade human embryonic stem cells. Compared to MSCs, CAStem stem cell injection has significant advantages in purity, uniformity, function, etc.